D. Arustamov

3 ta ish

Center of Urology, Ministry of Health of Republic of Uzbekistan, 700 109 Tashkent, Uzbekistan

1. Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

   F.M.J. Debruyne, A A Gres, D. Arustamov

   MaqolaUrinary Bladder and Prostate ResearchEuropean Urology20081 iqtibos

   ABIABI:AkademIndex/openalex/2008.article.000044

2. Study on the rate of the urnlithiasis in the Aral Sea Area and the quality of potable water

   D. Arustamov, Dilorom Fayzieva, R. B. Nurullaev +1

   MaqolaTransboundary Water Resource ManagementWIT transactions on biomedicine and health20011 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.104764

3. Reply to Tomasz Drewa and Piotr Chlosta's Letter to the Editor re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia. Eur Urol 2008;54:170–80

   F. Debruyne, A A Gres, D. Arustamov

   MaqolaUrinary Bladder and Prostate ResearchEuropean Urology20080 iqtibos

   ABIABI:AkademIndex/openalex/2008.article.000360